It was previously reported that inhibition of mek1 in the renal cell carcinoma xenograft model with acquired resistance to sunitinib successfully improved anti-tumor drug efficacy [47]. This evidence concerns the gene MAP2K1 and hereditary clear cell renal cell carcinoma.